Reduction in Belatacept Dosing Frequency to Every 2 Months for Kidney Transplant Patients at High Risk of Infections

Documenti analoghi

• Single‐Center Outcomes of Conversion to Belatacept in Kidney Transplant Recipients
  di: Eve Carciofi, et al.
  Pubblicazione: (2025)
• Epidemiology of Infections in Lung Transplant Recipients Treated With Belatacept
  di: Madeleine R. Heldman, et al.
  Pubblicazione: (2024)
• Outcomes of Kidney Transplants From Donors With Stage 3 Acute Kidney Injury Requiring Dialysis: A National Cohort Study
  di: Amber B. Paulus, et al.
  Pubblicazione: (2026)
• The Role of Belatacept‐Use and Senescence on Infectious and Mortality Complications After Kidney Transplantation
  di: Hareesh Singam, et al.
  Pubblicazione: (2026)
• Long‐Term Outcomes of Belatacept Versus Tacrolimus Following T‐Cell Depleting Induction in Adult Kidney Transplantation
  di: Laura E. Newton, et al.
  Pubblicazione: (2025)